Andrew H Talal

A framework for patient-centered telemedicine: Application and lessons learned from vulnerable populations

Marianthi Markatou, Elisavet M. Sofikitou, Andrew H Talal, 2020, J. Biomed. Informatics.

Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b.

Andrew H Talal, Ruy M Ribeiro, Alan S Perelson, 2003, Seminars in liver disease.

Pharmacodynamics of PEG‐IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders

Marianthi Markatou, Andrew H Talal, Ruy M Ribeiro, 2006, Hepatology.

Interferon γ-Inducible Protein 10: A Predictive Marker of Successful Treatment Response in Hepatitis C Virus/HIV-Coinfected Patients

Marianthi Markatou, Andrew H Talal, Marija Zeremski, 2007, JAIDS Journal of Acquired Immune Deficiency Syndromes.

Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd‐EOB‐DTPA‐enhanced MRI for hepatic fibrosis stage

Pascal Spincemaille, Krishna Juluru, Steven P Sourbron, 2017, Journal of magnetic resonance imaging : JMRI.

Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum α‐fetoprotein

Andrew H Talal, Luis Chiriboga, Herman Yee, 2004, Liver international : official journal of the International Association for the Study of the Liver.

Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.

Marianthi Markatou, Andrew H Talal, Marija Zeremski, 2009, The Journal of infectious diseases.

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.

Andrew H Talal, David Butera, C. Rice, 2005, Blood.